Fig 1: Diagnostic values of STX6 and AFP indicated by ROC curve analyses based on the TCGA and GTEx datasets. (A) Diagnostic value of STX6 assessed using ROC curve analysis of data from TCGA (tumor, n=374; normal, n=50). (B) Diagnostic value of STX6 assessed using ROC curve analysis of data from TCGA (tumor, n=371) and GTEx (normal, n=160) databases. (C) Diagnostic value of AFP assessed using ROC curve analysis of data from TCGA (tumor, n=374; normal, n=50). (D) Diagnostic value of AFP assessed using ROC curve analysis of data from TCGA (tumor, n=371) and GTEx (normal, n=160) databases. (E) Diagnostic value of STX6 assessed using ROC curve analysis of data from the present study (tumor, n=90; normal, n=12). AFP, α-fetoprotein; AUC, area under the curve; FPR, false positive rate; GTEx, Genotype-Tissue Expression; HCC, hepatocellular carcinoma; ROC, receiver operating characteristic; STX6, syntaxin 6; TCGA, The Cancer Genome Atlas; TPR, true positive rate.
Fig 2: Relationship between STX6 expression and immune cell infiltration levels in hepatocellular carcinoma. (A) Correlation of STX6 expression with tumor-infiltrating immune cells in LIHC (n=371). Scatter plots presenting the correlations between STX6 expression and marker molecules, including (B) TAMs (CCL2, CD68, IL10, VSIG4, MSR1, MS4A4A), and (C and D) CD163. The blue curve and gray area in the figure represent the general trend direction. LIHC, liver hepatocellular carcinoma; STX6, syntaxin 6; CCL2, CC motif chemokine ligand 2; MS4A4A, membrane spanning 4-domains A4A; MSR1, macrophage scavenger receptor 1; TAMs, tumor-associated macrophages; TPM, transcripts per million; VSIG4, V-set and immunoglobulin domain containing 4.
Fig 3: Predictive value of STX6 for prognosis in HCC. (A) OS in patients with the present HCC data. (B) OS analyzed using Kaplan-Meier plotter. (C) DFS and (D) OS analyzed using Gene Expression Profiling Integrative Analysis 2. DFS, disease-free survival; HCC, hepatocellular carcinoma; HR, hazard ratio; OS, overall survival; STX6, syntaxin 6.
Fig 4: Expression levels of STX6 and CD163 in HCC. (A) CD163 expression in HCC and adjacent noncancerous tissues (magnification, ×100). (B) IHC staining score of CD163 in HCC and adjacent noncancerous tissues. (C) STX6 and CD163 expression in paired paraffin-embedded tumor slices (magnification, ×100). (D) IHC score of CD163 in tumor tissues from patients in the high and low STX6 groups. (E) Correlation between the IHC score of STX6 and the IHC score of CD163. *P<0.05. HCC, hepatocellular carcinoma; IHC, immunohistochemistry; STX6, syntaxin 6.
Fig 5: STX6 protein expression in human HCC and paired adjacent tissues. (A) IHC staining of STX6 in HCC and paired adjacent tissues (magnification, ×100). (B) STX6 protein expression presented as the IHC staining score in 12 HCC and paired adjacent tissues. Data are presented as the mean ± SD. **P<0.01. HCC, hepatocellular carcinoma; IHC, immunohistochemistry; STX6, syntaxin 6.
Supplier Page from Abcam for Anti-Syntaxin 6 antibody [EP7665] - Golgi Membrane Marker